Citations

Mayo Clinic

Showing 10 of 108551 citations.

von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges
Botero, Juliana Perez , Pruthi, Rajiv K. , Nichols, William L., Ashrani, Aneel A. , Patnaik, Mrinal M. , Perez Botero, Juliana, Perez Botero, Juliana

British Journal of Haematology | March 12, 2016 | Volume: 176 | Issue: 6 | Pages: 994-997

10.1111/bjh.14028 | PMID 26970096 Get It

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
Williams, Michael E. , Gascoyne, Randy D. , Krauss, John C. , Swinnen, Lode J., Peterson, Christopher G., Sborov, Mark D., Martín, Sabrina , Weiss, Matthias , Ehmann, W. Christopher, Horning, Sandra J., Hong, Fangxin , Wagner, Lynne I. , Habermann, Thomas M. , Schuster, Stephen J. , Kahl, Brad S.

British Journal of Haematology | March 12, 2016 | Volume: 173 | Issue: 6 | Pages: 867-875

10.1111/bjh.14007 | PMID 26970533 Get It

SummaryThe rituximab extended schedule or retreatment trial (RESORT; E4402) was a phase 3 randomized prospective trial comparing maintenance rituximab (MR) versus a retreatment (RR) dosing strategy in asymptomatic, low tumour burden indolent lymphoma. A planned exploratory sub‐study compared the two strategies for small lymphocytic (SLL) and marginal zone lymphomas (MZL). Patients responding to rituximab weekly × 4 were randomized to MR (single dose rituximab every 3 months until treatment failure) or RR (rituximab weekly × 4) at the time of each progression until treatment failure. The primary endpoint was time to treatment failure (TTTF). Patients with SLL (n = 57), MZL (n = 71) and unclassifiable small B‐cell lymphoma (n = 3) received induction rituximab. The overall response rate (ORR) was 40% [95% confidence interval (CI) 31–49%; SLL ORR 22·8%; MZL ORR 52·1%]; all 52 responders were randomized. At a median of 4·3 years from randomization, treatment failure occurred in 18/23 RR and 15/29 MR. The median TTTF was 1·4 years for RR and 4·8 years for MR (P = 0·012); median time to first cytotoxic therapy was 6·3 years for RR and not reached for MR (P = 0·0002). Survival did not differ (P = 0·72). In low tumour burden SLL and MZL patients responding to rituximab induction, MR significantly improved TTTF as compared with RR.
Development and Validation of a Disease‐Specific Questionnaire to Assess Patient‐Reported Symptoms in Polycystic Liver Disease
Neijenhuis, Myrte K., Hogan, Marie C. , Kamath, Patrick S. , Wijnands, Titus F. M., Ouweland, Ralf C.P.M. van den, Edwards, Marie E., Sloan, Jeff A. , Kievit, Wietske , Drenth, Joost P.H. , Gevers, Tom J.G. , Hogan, Marie C , Drenth, Joost P H

Hepatology | March 12, 2016 | Volume: 64 | Issue: 1 | Pages: 151-160

10.1002/hep.28545 | PMID 26970415 Get It

Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD‐related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease‐specific questionnaire that assesses symptoms in PLD (PLD‐Q). We identified 16 PLD‐related symptoms (total score 0‐100 points) by literature review and interviews with patients and clinicians. The developed PLD‐Q was validated in Dutch (n = 200) and United States (US; n = 203) PLD patients. We assessed the correlation of PLD‐Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ‐5D, and liver volume. To test discriminative validity, we compared PLD‐Q total scores of patients with different PLD severity stages (Gigot classification) and PLD‐Q total scores of PLD patients with general controls and polycystic kidney disease patients without PLD. Reproducibility was tested by comparing original test scores with 2‐week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD‐Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = −0.517; US, r = −0.593) was good. There was no correlation of PLD‐Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type II patients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLD patients scored higher on the PLD‐Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney disease patients without PLD (22 points). Reproducibility of PLD‐Q was excellent (NL, r = 0.94; US, 0.96). Conclusion: PLD‐Q is a valid, reproducible, and sensitive disease‐specific questionnaire that can be used to assess PLD‐related symptoms in clinical care and future research. (Hepatology 2016;64:151–160)
Deregulated methionine adenosyltransferase α1, c‐Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans‡
Yang, Heping , Liu, Ting , Wang, Jiaohong, Li, Tony W.H., Fan, Wei , Peng, Hui , Krishnan, Anuradha , Mato, José M. , Lu, Shelly C. , Gores, Gregory J. , Lu, Shelly C.

Hepatology | March 12, 2016 | Volume: 64 | Issue: 2 | Pages: 439-455

10.1002/hep.28541 | PMID 26969892 Get It

c‐Myc induction drives cholestatic liver injury and cholangiocarcinoma (CCA) in mice, and induction of Maf proteins (MafG and c‐Maf) contributes to cholestatic liver injury, whereas S‐adenosylmethionine (SAMe) administration is protective. Here, we determined whether there is interplay between c‐Myc, Maf proteins, and methionine adenosyltransferase α1 (MATα1), which is responsible for SAMe biosynthesis in the liver. We used bile duct ligation (BDL) and lithocholic acid (LCA) treatment in mice as chronic cholestasis models, a murine CCA model, human CCA cell lines KMCH and Huh‐28, human liver cancer HepG2, and human CCA specimens to study gene and protein expression, protein‐protein interactions, molecular mechanisms, and functional outcomes. We found that c‐Myc, MATα1 (encoded by MAT1A), MafG, and c‐Maf interact with one another directly. MAT1A expression fell in hepatocytes and bile duct epithelial cells during chronic cholestasis and in murine and human CCA. The opposite occurred with c‐Myc, MafG, and c‐Maf expression. MATα1 interacts mainly with Mnt in normal liver, but this switches to c‐Maf, MafG, and c‐Myc in cholestatic livers and CCA. Promoter regions of these genes have E‐boxes that are bound by MATα1 and Mnt in normal liver and benign bile duct epithelial cells that switched to c‐Myc, c‐Maf, and MafG in cholestasis and CCA cells. E‐box positively regulates c‐Myc, MafG, and c‐Maf, but it negatively regulates MAT1A. MATα1 represses, whereas c‐Myc, MafG, and c‐Maf enhance, E‐box‐driven promoter activity. Knocking down MAT1A or overexpressing MafG or c‐Maf enhanced CCA growth and invasion in vivo. Conclusion: There is a novel interplay between MATα1, c‐Myc, and Maf proteins, and their deregulation during chronic cholestasis may facilitate CCA oncogenesis. (Hepatology 2016;64:439‐455)
An early look at the Organ Procurement and Transplantation Network explant pathology form data
Harper, Ann, Edwards, Erick, Edwards, Erick B., Washburn, W. Kenneth , Heimbach, Julie K.

Liver Transplantation | March 12, 2016 | Volume: 22 | Issue: 6 | Pages: 757-764

10.1002/lt.24441 | PMID 26970341 Get It

In April 2012, the Organ Procurement and Transplantation Network (OPTN) implemented an online explant pathology form for recipients of liver transplantation who received additional wait‐list priority for their diagnosis of hepatocellular carcinoma (HCC). The purpose of the form was to standardize the data being reported to the OPTN, which had been required since 2002 but were submitted to the OPTN in a variety of formats via facsimile. From April 2012 to December 2014, over 4500 explant forms were submitted, allowing for detailed analysis of the characteristics of the explanted livers. Data from the explant pathology forms were used to assess agreement with pretransplant imaging. Explant data were also used to assess the risk of recurrence. Of those with T2 priority, 55.7% were found to be stage T2 on explant. Extrahepatic spread (odds ratio [OR] = 6.8; P < 0.01), poor tumor differentiation (OR = 2.8; P < 0.01), microvascular invasion (OR = 2.6; P < 0.01), macrovascular invasion (OR = 3.2; P < 0.01), and whether the Milan stage based on the number and size of tumors on the explant form was T4 (OR = 2.4; P < 0.01) were the strongest predictors of recurrence. In conclusion, this analysis confirms earlier findings that showed an incomplete agreement between pretransplant imaging and posttransplant pathology in terms of HCC staging, though the number of patients with both no pretransplant treatment and no tumor in the explant was reduced from 20% to <1%. In addition, several factors were identified (eg, tumor burden, age, sex, region, ablative therapy, alpha‐fetoprotein, Milan stage, vascular invasion, satellite lesions, etc.) that were predictive of HCC recurrence, allowing for more targeted surveillance of high‐risk recipients. Continued evaluation of these data will help shape future guidelines or policy recommendations. Liver Transplantation 22 757–764 2016 AASLD.
Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy
Lynn, Amanda M., Singh, Siddharth , Congly, Stephen E. , Khemani, Disha, Johnson, David H., Wiesner, Russell H., Kamath, Patrick S. , Andrews, James C. , Leise, Michael D.

Liver Transplantation | March 12, 2016 | Volume: 22 | Issue: 6 | Pages: 723-731

10.1002/lt.24440 | PMID 26970243 Get It

Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which are possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically refractory HE. A retrospective evaluation of consecutive adult patients with medically refractory HE referred for PSS embolization at a tertiary center was performed (2003‐2015). Patient data collected included the type of HE, medications, Model for End‐Stage Liver Disease (MELD) score, shunt type, embolization approach, and materials used. Outcomes of interest were immediate (7 days), intermediate (1‐4 months), and longer‐term (6‐12 months) effectiveness and periprocedural safety. Effectiveness was determined based on changes in hospitalization frequency, HE medications, and symptoms. Twenty‐five patients with large PSS were evaluated for shunt embolization. Five were excluded due to high MELD scores (n = 1), comorbid conditions (n = 1), or technical considerations (n = 3). Of 20 patients who underwent embolization, 13 had persistent and 7 had recurrent HE; 100% (20/20) achieved immediate improvement. Durable benefit was achieved in 100% (18/18) and 92% (11/12) at 1‐4 and 6‐12 months, respectively. The majority (67%; 8/12) were free from HE‐related hospitalizations over 1 year; 10% developed procedural complications, and all resolved. Six developed new or worsening ascites. In conclusion, PSS embolization is a safe and effective treatment strategy that should be considered for select patients with medically refractory HE. Liver Transplantation 22 723–731 2016 AASLD.
Incidence of atypical nevi in Olmsted County: an epidemiological study
Adaji, Afolake, Gaba, Prakriti , Lohse, Christine M. , Brewer, Jerry D.

Journal of Cutaneous Pathology | March 12, 2016 | Volume: 43 | Issue: 7 | Pages: 557-563

10.1111/cup.12709 | PMID 26969303 Get It

BackgroundThe association of atypical nevi with melanoma and other forms of skin cancer has not been clearly defined.MethodsWe studied 631 patients with first lifetime diagnosis of mild, moderate or severely atypical nevus from 2000 through 2005, identified through a population‐based approach.ResultsAge at first diagnosis differed significantly between men and women (p<.001). Incidence rates peaked in the second through fourth decades in women and in the third, sixth and seventh decades in men. From 2000 through 2005, the overall age‐ and sex‐adjusted incidence rate of all degrees of atypical nevi was 76.0 per 100,000 person‐years. There were no statistically significant associations identified between the degree of atypia and the future development of basal cell carcinoma, squamous cell carcinoma or MM (p = 0.51, p = 0.28 and p = 0.19, respectively).ConclusionThere is no association between atypical nevi and the subsequent development of non‐melanoma skin cancer and MM. Incidence rates of atypical nevi are higher among younger women and older men. The association between degree of atypia and malignant melanoma warrants further study.
Is Psychological Stress a Factor for Incorporation Into Future Closed-Loop Systems?
Gonder‐Frederick, Linda , Brown, Sue A. , Patek, Stephen D., Basu, Ananda , Pinsker, Jordan E. , Kudva, Yogish C. , Wakeman, Christian, Dassau, Eyal , Zisser, Howard , Grabman, Jesse H. , Kovatchev, Boris , Cobelli, Claudio , Doyle, Francis J.

Journal of Diabetes Science and Technology | March 11, 2016 | Volume: 10 | Issue: 3 | Pages: 640-646

10.1177/1932296816635199 | PMID 26969142 Get It

Background: The relationship between daily psychological stress and BG fluctuations in type 1 diabetes (T1DM) is unclear. More research is needed to determine if stress-related BG changes should be considered in glucose control algorithms. This study in the usual free-living environment examined relationships among routine daily stressors and BG profile measures generated from CGM readings. Methods: A total of 33 participants with T1DM on insulin pumps wore a CGM device for 1 week and recorded daily ratings of psychological stress, carbohydrates, and insulin boluses. Results: Within-subjects ANCOVAs found a significant relationship between daily stress and indices of BG variability/instability ( r = .172 to .185, P = .011 to .018, r 2 = 2.97% to 3.43%), increased % time in hypoglycemia ( r = .153, P = .036, r 2 = 2.33%) and decreased carbohydrate consumption ( r = –.157, P = .031, r 2 = 2.47%). Models accounted for more variance for individuals reporting the highest daily stress. There was no relationship between stress and mean daily glucose or low/high glucose risk indices. Conclusions: These preliminary findings suggest that naturally occurring daily stressors can be associated with increased glucose instability and hypoglycemia, as well as decreased food consumption. In addition, findings support the hypothesis that some individuals are more metabolically reactive to stress. More rigorous studies using CGM technology are needed to understand whether the impact of daily stress on BG is clinically meaningful and if it is a behavioral factor that should be considered in glucose control systems for some individuals.
Acquired lymphangiectasia (lymphangioma circumscriptum) of the vulva: Clinicopathologic study of 11 patients from a single institution and 67 from the literature
Chang, Michael B., Newman, Catherine C., Davis, Mark D. P. , Lehman, Julia S. , Davis, Mark D.P. , Lehman, Julia S

International Journal of Dermatology | March 11, 2016 | Volume: 55 | Issue: 9 | Pages: No page available

10.1111/ijd.13264 | PMID 26967121 Get It

Abstract Background Acquired lymphangiectasia of the vulva ( ALV ) is a rare condition thought to be secondary to pelvic lymphatic obstruction. Although benign, this entity often occurs after previous malignancy and can be confused with conditions such as genital warts. We sought to clarify the clinicopathologic features of ALV by studying affected patients from our institution and from the existing literature. Methods We reviewed retrospectively the clinical and histopathologic characteristics of patients with ALV from our institution and performed an extensive literature search to identify all published cases of ALV . Results Eleven patients with ALV were identified from our institution. Three patients had Crohn disease, three had malignancies involving the pelvic region (rectal adenocarcinoma, cervical carcinoma, endometrial carcinoma), and three (two with pelvic malignancy) had previous radiation therapy. One patient had Proteus syndrome. Of 67 distinct cases of ALV identified in the literature, 41 (61%) had a history of malignancy. Conclusions In any acquired or clinically unusual lymphatic process in the skin and soft tissues, a lesion or obstructive process of the draining lymphatics should be investigated.
En bloc resection of a C-1 lateral mass osteosarcoma: technical note
Cloft, Harry J. , Segura, Leal G. , Hill, Cindy A., Browning, Meghen B., Brandt, Jon M., Lew, Sean M. , Foy, Andrew , Clarke, Michelle J. , Price, Daniel L.

Journal of Neurosurgery: Pediatrics | March 11, 2016 | Volume: 18 | Issue: 1 | Pages: 46-52

10.3171/2015.12.peds15496 | PMID 26966885 Get It

Osteosarcoma is an aggressive primary bone tumor. It is currently treated with multimodality therapy including en bloc resection, which has been demonstrated to confer a survival benefit over intralesional resection. The authors present the case of an 8-year-old girl with a C-1 lateral mass osteosarcoma, which was treated with a 4-stage en bloc resection and spinal reconstruction. While technically complex, the feasibility of en bloc resection for spinal osteosarcoma should be explored in the pediatric population.